In patients initiating first-line crizotinib therapy, lorlatinib demonstrated efficacy for crizotinib-refractory ALK-positive NSCLC in a phase II trial that included cohorts with (n = 32, EXP3A) or without (n = 27, EXP2) prior chemotherapy [78]. Here, ALK is linked to non-small cell lung carcinoma.